# GLP-1s and Cancer: What the Cohorts Actually Show

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-and-cancer-risk-what-the-cohorts-show

> One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.

## Key points

- HR 0.09 vs insulin and no difference vs SGLT2 inhibitors, for the same drug in the same study.
- The believable finding: 7.5 vs 8.1 obesity-related cancers per 1,000 person-years (HR 0.87).
- It pointed the same way against all six comparators, from 0.70 against insulin to 0.90 against metformin.
- Distrust hazard ratios below 0.5 in observational data. They usually describe who got prescribed.

Two large cohort studies looked at GLP-1 drugs and cancer. One found a modest reduction in obesity-related cancers that is probably real. The other reported that [breast cancer patients on these drugs](https://glpwatchdog.org/research/lists/top-glp1-cancer-survivor-outcomes-studies) had **91% lower mortality** than those on insulin or metformin. The same paper found **no difference at all** compared with a different diabetes drug, and that contradiction is the most instructive thing in it.

## The believable finding

A nationwide cohort published in the Journal of the National Cancer Institute followed 919,609 overweight or obese adults with type 2 diabetes in the United States between 2016 and mid-2021. Across 2,086,526 person-years, 16,653 were newly diagnosed with one of thirteen obesity-related cancers.[1]

GLP-1 users had an incidence of 7.5 per 1,000 person-years against 8.1 for users of other glucose-lowering drugs, an adjusted hazard ratio of **0.87**. The association held against each of six separate comparators: metformin 0.90, DPP-4 inhibitors 0.88, thiazolidinediones 0.84, sulfonylureas 0.81, SGLT2 inhibitors 0.73 and insulin 0.70.[1]

> **This is what a credible observational finding looks like.** The effect is small. The absolute difference is smaller still: six-tenths of a case per thousand person-years. And it points the same way against every comparison group, which makes confounding less likely as the whole explanation. The strongest figure, 0.70, is against insulin, the comparison group with the sickest patients, a pattern the next section explains.

## The finding that teaches you something

A 2026 cohort in JAMA Network Open examined 841,831 patients with breast cancer, and after propensity score matching compared three pairings. The results were spectacular and internally inconsistent in a specific way.[2]

*One study, one drug class, three comparison groups. The right-hand column is the whole lesson.*

| GLP-1 compared against | Matched patients | All-cause mortality |
| --- | --- | --- |
| Non-users (patients with obesity) | 1,610 | HR 0.35 (95% CI 0.21–0.58) |
| Insulin or metformin (patients with T2D) | 2,323 | HR 0.09 (95% CI 0.06–0.15) |
| **SGLT2 inhibitors (patients with T2D)** | 4,052 | **No significant difference** |

A hazard ratio of 0.09 means 91% lower mortality over ten years. No drug does that in breast cancer, chemotherapy included. A number like that comes from the comparison group, not from pharmacology.

> Against insulin or metformin, the hazard ratio for death was 0.09. Against SGLT2 inhibitors, in the same study, there was no significant difference.

People on insulin have, on average, longer-standing and worse-controlled diabetes, more complications and worse general health than people started on a GLP-1. Comparing the two measures how sick each group was before anyone prescribed anything. The SGLT2 comparison removes most of that difference (similar era, similar patients, similar prescribing logic), and the effect disappears with it. The same pattern turned up in [people being treated for cancer](https://glpwatchdog.org/research/glp1s-in-people-being-treated-for-cancer), where the insulin comparison produced the bigger and less trustworthy number.

## How to read any study like this

1. **Find the comparison group before the result.** “Lower risk” is meaningless until you know lower than what. A drug compared against sicker patients will always look good.
2. **Distrust enormous effects in observational data.** Hazard ratios below about 0.5 in a non-randomized study are usually a description of who was prescribed the drug.
3. **Look for consistency across comparators.** The JNCI result held at 0.70 to 0.90 across six; the breast cancer result went from 0.09 to nothing across three.
4. **Convert to absolute numbers.** The “13% lower risk” sits on rates of 7.5 against 8.1 per 1,000 person-years, and those land very differently.
5. **Note what the authors themselves say.** The breast cancer authors call for randomized trials, which is the appropriate conclusion from their own data; what the randomized trials already show for breast cancer is summarized in [GLP-1 drugs and breast changes](https://glpwatchdog.org/research/glp1-and-breast-changes).

## So what is known

GLP-1 use is associated with a slightly lower rate of obesity-related cancers in people with type 2 diabetes, by roughly a tenth, consistently across comparators. That is a real finding and a modest one, and it is entirely plausible: obesity is a recognized driver of those thirteen cancer types, and these drugs reduce obesity. A cohort of [obese adults without diabetes](https://glpwatchdog.org/research/cancer-risk-in-people-without-diabetes) reported a larger drop, 41%, over a median follow-up of only two years.

The randomized evidence, which we cover in [the trials’ answer on cancer](https://glpwatchdog.org/research/glp1-cancer-risk-the-randomized-answer), points at little or no effect in either direction, which is consistent with a small association that observational data can see and short trials cannot. What is not known is whether they improve survival in people who already have cancer. The evidence claiming so does not survive contact with a fair comparison group. If you are being treated for cancer, this is a question for your oncologist, and our [thyroid cancer article](https://glpwatchdog.org/research/glp1-thyroid-cancer-risk) covers the separate matter of the boxed warning that appears on every label in this class.

> None of this makes a GLP-1 a cancer treatment or a cancer preventive, and no such indication exists. Nor is it a reason for alarm in the other direction: nothing in these cohorts suggests increased cancer risk.

## Frequently asked questions

### Do GLP-1 drugs reduce cancer risk?

There is a modest association. In a cohort of 919,609 overweight or obese adults with type 2 diabetes, GLP-1 users had 7.5 obesity-related cancers per 1,000 person-years against 8.1 for other glucose-lowering drugs, a hazard ratio of 0.87, consistent across six different comparison drugs. It is small, plausible and not the same as prevention.

### A study said GLP-1s cut breast cancer mortality by 91%. Is that real?

Almost certainly not. The same study found no significant difference when GLP-1 users were compared with people taking SGLT2 inhibitors instead of insulin. The 91% figure comes from comparing against insulin users, who have more advanced diabetes and worse health before any drug is given.

### Why does the comparison group matter so much?

Because in a non-randomized study, the two groups differ in ways beyond the drug. Insulin marks longer-standing, worse-controlled diabetes. Comparing a GLP-1 against it measures how sick each group already was. A like-for-like comparator removes most of that, and here the effect vanished when one was used.

### Should someone with cancer take a GLP-1 for survival benefit?

There is no good evidence for that, and the authors of the breast cancer study call for randomized trials rather than claiming one. If you are being treated for cancer, this belongs with your oncologist.

### Do GLP-1 drugs cause cancer?

Nothing in these cohorts suggests increased risk. The thyroid C-cell warning that appears on every label in this class is a separate question with its own evidence, covered in our thyroid cancer article.

## References

1. Mao X, Zhang X, Henry L, et al. Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study. Journal of the National Cancer Institute. 2025. PMID: 40632592. https://pubmed.ncbi.nlm.nih.gov/40632592/
2. Tatum KL, Dahman B, Stevenson A, et al. Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. JAMA Network Open. 2026. PMID: 42113513. https://pubmed.ncbi.nlm.nih.gov/42113513/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s and Cancer: What the Cohorts Actually Show", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1-and-cancer-risk-what-the-cohorts-show

Canonical HTML page: https://glpwatchdog.org/research/glp1-and-cancer-risk-what-the-cohorts-show

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
